{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:41Z","timestamp":1788887081552,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:14:28Z","timestamp":1719418468000},"page":"783-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4527-0500","authenticated-orcid":false,"given":"Julie S.","family":"Braish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Short","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.06.007_bib0001","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.clinthera.2007.09.002","article-title":"Nelarabine: a novel purine antimetabolite antineoplastic agent","volume":"29","author":"Buie","year":"2007","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.06.007_bib0002","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.06.007_bib0003","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.06.007_bib0004","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.clml.2024.06.007_bib0005","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children's oncology group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.06.007_bib0006","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.06.007_bib0007","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Gokbuget","year":"2011","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2024.06.007_bib0008","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.06.007_bib0009","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2024.06.007_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.06.007_bib0011","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-006-0328-0","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates","volume":"59","author":"Berg","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.clml.2024.06.007_bib0012","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.06.007_bib0013","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1200\/JCO.2012.45.4728","article-title":"Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia","volume":"31","author":"Gollard","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.06.007_bib0014","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.clml.2024.06.007_bib0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Van Den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.clml.2024.06.007_bib0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00003495-200868040-00004","article-title":"Nelarabine","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs."},{"key":"10.1016\/j.clml.2024.06.007_bib0017","first-page":"1135","article-title":"Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"3","author":"Cooper","year":"2007","journal-title":"Ther Clin Risk Manage"},{"issue":"1","key":"10.1016\/j.clml.2024.06.007_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.clml.2024.06.007_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.06.007_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.06.007_bib0021","first-page":"296","article-title":"Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: case report and review of literature","volume":"21","author":"Ngo","year":"2014","journal-title":"Sage J"},{"issue":"10","key":"10.1016\/j.clml.2024.06.007_bib0022","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.23502","article-title":"Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine","volume":"88","author":"Kawakami","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.007_bib0023","article-title":"ClinicaI reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication","volume":"7","author":"Tisi","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2024.06.007_bib0024","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:50Z","timestamp":1729595390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002416"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}